Autoimmune thyroid disease (AITD) may occur in patients after hematopoietic stem cell transplantation (HSCT). In all, 10 cases of AITD (seven allogeneic and three autologous HSCT) were diagnosed among 721 HSCT recipients, including two patients with sequential hyper-and hypothyroidism. The 5-year actuarial rates for AITD after allogeneic and autologous HSCT were 2.9 and 4%, respectively. Significant risk factors included HSCT for chronic myeloid leukemia, the HLA B46 and DR9 loci and the A2B46DR9 haplotype, while female donors showed trend to significance. On multivariate analysis, only female donors and HLA DR9 remained significant. For autologous HSCT, the associations with HLA B46 and DR9 were also significant. Only three donors had a family history of AITD. A review of other reported cases confirmed the predominance of female donors, although the other associations including graftversus-host disease, familial AITD and other autoimmune phenomena might be related to reporting bias. Since the actuarial incidence of AITD from female donors with predisposing HLA alleles may be over 30%, susceptible recipients should be carefully monitored. Owing to the small number of reported cases and different HLA associations with AITD in different populations, our observations await confirmatory data from other registries.
However, most previous studies are case reports, and the incidence and risk factors are poorly defined. Owing to reporting bias, many published accounts are those of direct adoptive immunotransfer from donors with documented AITD. Our group have previous reported the close association between AITD and the HLA A2B46DR9 haplotype in Southern Chinese patients. 3 We update our experience on the largest single center collection of post-HSCT AITD and review the reported literature on this entity.
Patients and methods

Patients
All Chinese adult patients undergoing allogeneic or autologous HSCT from 1991 to 2003 were studied. Antithyroglobulin (Tg) and microsomal (Tm) antibodies (Ab) were assayed by a particle agglutination test. Thyroid function tests, including free thyroxine (fT4) and thyroid-stimulating hormone (TSH), and anti-Tg and anti-Tm Ab (particle agglutination test, normal o1 in 100), were tested in recipients and donors before HSCT. This was repeated at 1-year follow-up, and every 2 years thereafter. AITD was defined as persistent symptomatic thyroid dysfunction with elevation of anti-Tg or anti-Tm Ab (above 1 in 400).
Statistical analysis
A Kaplan-Meier analysis was performed using a Cox model, to analyze the risk of AITD associated with HLA alleles A2, B46 and DR9, donor and recipient gender, total body irradiation (TBI) and graft-versus-host disease (GVHD). Patients were censored at death, last follow-up or at the development of AITD (SPSS 10.0, Chicago, IL, USA). Factors with P-values below 0.1 were further entered into multivariate analysis. Finally, a proportional hazards analysis was used to calculate the relative risks (RR) of AITD at latest follow-up with 95% confidence intervals (CI).
Results
HSCT recipients
A total of 721 Chinese patients undergoing allogeneic (n ¼ 550) and autologous (n ¼ 171) HSCT were studied. The median age was 35 (18-65) years for allogeneic and 42 (18-67) years for autologous cases. The median follow-up was 36 and 27 months for allogeneic and autologous HSCT. The male to female (M:F) ratio was 1.42 for allogeneic and 0.99 for autologous HSCT.
HSCT donors
For all allogeneic cases, the ratio of male to female donors was 1.01 and the median age was 34 (8-68) years. Donors included HLA-matched sibling (n ¼ 457), matched unrelated (n ¼ 74) and one HLA-mismatched sibling or parent (n ¼ 19). The source of HSC was marrow in 528 cases, and peripheral blood in 24 cases.
HSCT recipients developing AITD
In all, 10 patients with post-HSCT AITD were identified (Table 1) , of whom four (cases 1, 5-7) had previously been reported. 3 The presentation was hyperthyroidism in five cases, hypothyroidism in three cases and sequential hyperand hypothyroidism in two cases. The median age at HSCT was 36 (19-55) years. The onset of AITD from HSCT was 34 (12-66) months. The levels of anti-Tg/Tm Ab were raised in all cases (ranged 1600 to over 1 Â 10 8 U). Three cases had mild symptoms (sweating, lethargy and palpitation), while others presented more florid clinical features, including severe weight loss, tremor, cardiac temponade and severe depression. For thyrotoxic cases, the median fT4 and TSH levels were 46 (13-123) mmol/l (13-123) and o0.03 (o0.03-8) IU/l. In hypothyroid cases, the median fT4 and TSH levels were 8 (o1.3-9) mmol/l and 25 (23-157) IU/l. Two recipients died of progressive myeloma.
Allogeneic donors
The median age of seven allogeneic donors was 32 (8-51) years, and included six sister sibling donors and one male unrelated donor. Familial AITD may be implicated in three cases (42%): one donor had history of thryotoxicosis, one had asymptomatic elevated Tg/Tm, and another had family history of thyrotoxicosis in an unmatched sibling (Table 1) . Two CML patients developed sequential thyrotoxicosis and hypothyroidism due to HSCT and interferon (IFN) therapy. Case 9 received a one-antigen mismatched marrow from her sister, due to a lack of cytogenetic response to IFN. She rejected the graft with autologous regeneration. Resumption of IFN at 10 months post-HSCT resulted in profound hypothyroidism with severe depression and suicidal ideas. IFN was stopped with 2 months of thyroxine replacement. She was started on imatinib mesylate (STI), resulting in complete cytogenetic response, but developed severe cachexia and hyperthyroidism, requiring carbimazole treatment for 2 years. At 3-year follow-up, she was euthyroid, with only molecular evidence of CML on STI alone. Case 10 achieved major cytogenetic response with IFN treatment, which was stopped due to severe cachexia and hyperthyroidism, requiring carbimazole treatment pre-HSCT. She became euthyroid with mild GVHD after unrelated HSCT, but 2 years later developed severe hypothyroidism with no molecular evidence of CML relapse.
Statistical analysis
The results of statistical analysis of risk factors for AITD are shown in Tables 2a and b . For autologous HSCT, only 48 cases were HLA typed. GVHD was not assessable for cases with early deaths and nonengraftment. On univariate analysis for allogeneic HSCT, there were significant associations between HSCT for CML, female donor, the HLA B46 and DR9 loci and the A2B46DR9 haplotype with post-HSCT AITD. On multivariate analysis, significant association was only found for female donors and HLA DR9. For autologous HSCT, the association with HLA B46 and DR9 was also significant. The 5-year actuarial rates for AITD after allogeneic and autologous HSCT were 2.9 and 4%, respectively, which were not statistically different by Kaplan-Meier analysis. The rate in patients with HLA A2B46DR9 haplotype was 15% for allogeneic HSCT, which increased to 31% for recipients with female donors.
Discussion
This is the largest cohort of post-HSCT AITD and the only single center series. Previous reported series of thyroid dysfunction post-HSCT focused on postradiation hypothyroidism 4, 5 and sick euthyroid syndrome-like compensated hypothyroidism early after high-dose chemotherapy conditioning, 6, 7 and the incidence of clinically significant autoimmune thyroid dysfunction after HSCT is largely unknown. One screening study showed that thyroid damage after HSCT causing transient subclinical hyperthyroidism and low-titer thyroid antibodies may be common. 7 However, the occurrence of sustained autoimmune thyroid dysfunction in the form of Graves disease or Hashimoto thyroiditis appeared to be rarer and is mainly limited to case reports ( Table 3 ). The incidence of postirradiation hypothyroidism in updated HSCT series was low and not encountered in our adult series, while sick euthyroid syndrome usually did not warrant endocrine treatment. On the other hand, up to 3% of the post-SCT population may suffer from AITD after 5 years of followup.
The lifetime risk of de novo AITD in the general population varied from 2 to 4% with a female to male ratio of 3:1. There is strong familial tendency as well as ethnic HLA association, namely A2B46DR9 in Chinese, B35 and B46 in Japanese and A1B8DR3 in Caucasians. 4, [8] [9] [10] [11] We showed that post-SCT AITD in Chinese has the same HLA and donor sex associations as in de novo AITD. Three factors may have triggered such HLA-related AITD: namely, inherent patient susceptibility, the effect of conditioning chemotherapy and radiotherapy, and the graftversus-host effect of the infused lymphocytes. 12 Several features of our results suggested that the effect of donor lymphocytes on the recipient thyroid system carried the most significant role. Firstly, the 5-year actuarial rates are much higher than that proportionally expected from inherent lifetime risks in the SCT age group. Secondly, AITD, and in particular hyperthyroidism, is rarely reported in lymphoma and leukemia cases receiving chemotherapy and/or radiotherapy alone without stem cell infusion. 13 Finally, the strong association with female donor lymphocytes but the lack of association with recipient sex strongly suggests a stronger pathogenetic role for the infused lymphoid cells. The stronger association with DR9 is interesting, since preliminary results from our populations have shown stronger associations with B46 for de novo Graves disease 14 and DR9 for de novo Hashimoto thyroiditis. 15 It is likely that a variety of auto-antibodies coexist, and changes in immune environment or dominant T-cell population may trigger a shift in the balance between hyper-and hypothyroidism.
It is interesting to compare the collection of published case reports with our single center experience. Post-HSCT AITD was first reported in 1987, 16 and a total 17 cases have since been reported (Table 3) . [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] They included five cases of hypothyroidism and 12 cases of thyrotoxicosis. The male to female ratio in HSCT recipients was roughly equal (1.83:1), but similar to our experience, donors were markedly skewed to females (0.23:1). The median age of recipients was 25 (1.5-50) years, while that of donor was 29 (12-64) years. Unlike our series, the indication for HSCT was more varied, the most common being aplastic anemia (n ¼ 6). Others included acute myeloid leukemia (n ¼ 5), CML (n ¼ 3) and acute lymphoblastic leukemia (n ¼ 2). The use of TBI (n ¼ 8) was comparable to our series. The median time from HSCT to the onset of AITD was 19 (5-113) months. Five cases did not require treatment, and antithyroid drugs and thyroxine were used in 10 and 2 cases. At the latest follow-up, two patients had become euthyroid, one hypothyroid and one case required radioactive iodine therapy. 16 HLA typing details were reported in 10 cases, including ethnic-specific AITD-linked alleles (A1B8DR3, B35 and A2B46DR9) in several cases. However, the ethnic diversity (5 Oriental, 12 Caucasian) and lack of comparison with the HLA makeup of background and transplanted populations hindered further interpretation. Compared with our series, these reported cases showed some discordant features. Firstly, acute GVHD (reported in 14/17 cases) was more common than in our experience, and five cases had significant chronic GVHD. Secondly, the majority (12/17, 70.5%) of donors had AITD in the form of preceding, silent 17, 24, 26 or subsequent hyperor hypothyroidism. 20, 21 Donors and recipients often had discordant hyper-or hypothyroidism, 23, 27 which was not seen in our series. Thirdly, there was also a high incidence of concomitant autoimmune diseases in the recipients, including diabetes, 21 psoriasis, 24 vitiligo 27 and nephrotic syndrome. 28 Interestingly, a pharmacological trigger, lithium, was implicated in two cases. 30, 32 These features were not seen in our series of consecutive cases of post-HSCT AITD.
Clinically, physicians should have a high index of suspicion since AITD may appear late after HSCT, and without associated features of GVHD. The onset of symptoms may be rapid and florid. Patients with susceptible HLA combinations (in their ethnic group) should be more closely followed up, and encouraged to report symptoms related to thyroid dysfunction. Extra precaution may also be warranted for female donors and or in families with a strong history of AITD. In most cases, however, the onset of AITD is not related to previous history of AITD 
